For decades, GxP compliance ran on a straightforward premise: validate a system once, document it thoroughly, and treat that validated state as proof. That premise is now under pressure. In September 2025 the FDA finalized its Computer Software Assurance guidance, moving the emphasis away from documentation-heavy validation toward a risk-based model built on intended use and real-world evidence. It is the clearest signal yet that GxP validation vs verification is no longer a paperwork distinction. It is an operational one.
The old question was whether a system was validated on the day it went live. The new one is whether you can show it has stayed in control ever since. For pharmaceutical and life sciences leaders, this shift toward continuous validation is less a QA exercise than a test of how consistently GxP IT systems are delivered and maintained across sites, vendors, and regions. And that makes it a board-level concern.
The Shift from Validation to Verification
Traditional validation was built to answer one question at one moment: does this system do what it is supposed to do, right now, on the record? Verification asks something harder. It asks whether that system has stayed in a validated, controlled state every day since. The FDA’s Computer Software Assurance guidance, first finalized in September 2025 and updated in February 2026, captures the shift precisely. It steers organizations away from exhaustive, documentation-led testing and toward a risk-based model that weighs intended use, patient-safety impact, and real-world evidence of performance. In doing so, it retired the documentation-heavy validation model that had defined the discipline for a generation.
This is not only an FDA story. In July 2025, the European Commission and PIC/S published the first full rewrite of Annex 11, their guidance for computerized systems, in more than a decade. It resets the expectation from initial validation alone to control across the entire system lifecycle, and it aligns deliberately with the FDA’s direction. Because PIC/S spans regulators across the US, UK, and Asia-Pacific, that alignment holds wherever pharmaceutical companies operate. The message is consistent across jurisdictions, and it reframes the old GxP validation vs verification debate: continuous validation, not a one-time sign-off, is becoming the baseline.
Validation is no longer a milestone you pass. It is a state you are expected to maintain.
Where Traditional Validation Falls Short
The problem is not that validation is wrong. It is that validation, as traditionally practiced, produces a snapshot: proof that a system was fit for purpose on the day it was signed off. IT environments do not stand still. Between one review and the next, the live system keeps moving:
- Patches and updates land
- Configurations shift
- Access is granted and revoked
- Integrations and dependencies change
Each change nudges the running system a little further from the state that was originally validated. This is the structural weakness in traditional pharmaceutical IT validation: it certifies a moment, not a lifecycle. Over time, the documented validated state and the system actually running in production quietly diverge, and the gap is rarely visible until an audit or an incident exposes it.
That gap widens fastest across globally distributed GxP IT systems, where the same platform is built and maintained differently from site to site, and where central teams have limited visibility into what has changed, where, and by whom. The consequences are well documented. The patterns inside recent FDA warning letters point repeatedly to controls that existed on paper but had drifted in practice. Regulators increasingly treat these findings as systemic rather than procedural: in 87% of the 2025 drug GMP warning letters reviewed by regulatory consultancy The FDA Group, the agency, had recommended bringing in external GMP expertise, a signal that these are structural gaps in how quality and IT are run day to day, not isolated mistakes.
The failure point is rarely the original validation. It is everything that happens to the environment afterward.
Supporting Continuous Assurance in GxP IT
If validation cannot hold a system in a controlled state on its own, the answer is not more validation. It is a delivery model built to keep the environment consistent and controlled every day, across every site. This is where consistent IT delivery stops being an operational detail and becomes a compliance control in its own right. Maintech supports GxP environments in five connected ways:
Standardize every environment: Consistent builds, configurations, and identity across all locations, with central control over change and no local exceptions outside a documented process, so environments cannot quietly drift apart.
Deliver through one operating model: A single, unified delivery model means control behaves the same way in New Jersey, London, or Singapore, rather than depending on which team happens to maintain which site.
Monitor continuously: This is where compliance monitoring IT becomes a live, managed capability across systems, access, and activity, catching change as it happens instead of at the next audit.
Hold the validated state: Change control, access recertification, and audit trail review are built into daily operations, so validated and controlled states are maintained over time, not just established once and left to erode.
Scale within a controlled framework: Infrastructure that absorbs growth, new sites, and new requirements while staying aligned to GxP, so expansion does not mean re-engineering compliance from scratch.
Delivered this way, continuous assurance stops being a project you complete and becomes a property of the environment itself. It is the difference between passing your next audit and being ready for one at any time.
Closing the Gap Between Validation and Verification
The GxP validation vs. verification question is no longer really about paperwork. It is about what compliance now demands. Validation still matters, but on its own it captures a moment. Verification captures the days, months, and years that follow. As the FDA and European regulators converge on continuous, risk-based expectations, the organizations that stay in control will be the ones that can demonstrate it at any time, not only on the day a system goes live.
That capability is not built in a validation report. It is built into how IT environments are delivered and maintained, consistently, across every site and every day. Compliance has become an operational outcome, and the case for standardized, continuously monitored GxP IT systems has never been clearer.
GxP compliance is evolving from validation to continuous verification. Maintaining control now depends on how consistently IT environments are managed over time.
Speak with a Maintech expert to assess how your IT environment supports continuous GxP assurance.
Frequently Asked Questions
What is the data center asset lifecycle?
The data center asset lifecycle covers every stage a piece of equipment goes through. Managing it well means keeping accurate records throughout, especially in the stages between installation and decommissioning.
How often should data center asset records be audited?
Most organizations benefit from scheduled physical audits at least once or twice a year, with updates logged continuously as installs, moves, additions, and changes happen. Waiting for an annual review to catch every discrepancy leaves too much room for the record to drift from reality.
What happens to data-bearing components during decommissioning?
Data-bearing components such as hard drives and storage arrays go through documented sanitization or destruction to a defined standard, with each step tied to the device’s serial number. This creates an auditable record that proves the data was handled securely.
Can decommissioned data center equipment be resold or reused?
Yes, decommissioned data center equipment can often be resold or reused. Equipment that’s still functional can be redeployed into a secondary role or resold through a certified reseller. Only assets that have reached the end of their useful life should move to certified recycling.
